1. Home
  2. ABUS vs HAFC Comparison

ABUS vs HAFC Comparison

Compare ABUS & HAFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.25

Market Cap

848.8M

Sector

Health Care

ML Signal

HOLD

Logo Hanmi Financial Corporation

HAFC

Hanmi Financial Corporation

HOLD

Current Price

$28.95

Market Cap

821.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABUS
HAFC
Founded
2005
1982
Country
United States
United States
Employees
19
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
848.8M
821.2M
IPO Year
2008
2000

Fundamental Metrics

Financial Performance
Metric
ABUS
HAFC
Price
$4.25
$28.95
Analyst Decision
Strong Buy
Hold
Analyst Count
1
3
Target Price
$5.00
$32.17
AVG Volume (30 Days)
1.6M
225.8K
Earning Date
05-14-2026
04-21-2026
Dividend Yield
N/A
3.75%
EPS Growth
55.26
22.44
EPS
0.87
0.75
Revenue
$14,083,000.00
$270,165,000.00
Revenue This Year
N/A
$18.65
Revenue Next Year
$239.71
$7.28
P/E Ratio
$4.95
$38.96
Revenue Growth
128.21
15.28
52 Week Low
$3.04
$21.84
52 Week High
$5.10
$31.33

Technical Indicators

Market Signals
Indicator
ABUS
HAFC
Relative Strength Index (RSI) 45.31 49.75
Support Level $4.17 $26.13
Resistance Level $4.62 $29.46
Average True Range (ATR) 0.16 0.66
MACD -0.00 -0.23
Stochastic Oscillator 46.23 10.28

Price Performance

Historical Comparison
ABUS
HAFC

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About HAFC Hanmi Financial Corporation

Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.

Share on Social Networks: